Adherence to treatment with tyrosine kinase inhibitors

• Autores: A. Pérez Feliú, J.L. Marco Garbayo, Pilar Blasco Segura, Isabel Pérez Castelló, E. Peiró Barber
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 15, Nº. 6, 2013, pág. 2
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objective: To assess the adherence to the Tyrosine-Kinase Inhibitors(TKI) therapy and to analyze the influence of several factors on the adherence.

    Method: A one-year retrospective study. Adherence was defined as the proportion of days covered regarding total of days observed.

    Data was obtained from the dispensing registrations and medical records: age, sex, diagnosis, drug, dose (number of tablets and frequency), change in dose/treatment, duration of prior treatment, reported Adverse Drug Reactions (ADR) by the patient, cause of withdrawal and exitus.

    Results: 66 patients were included in the study, 44 males with a mean age of 60.2 years. The median of adherence was 97.31%, 18.2% of patients presented adherence below 85%. The realtion between adherence and the studied variables did not show any statistically significant relation.

    Conclusions: Monitoring of the adherence to oral antineoplastics therapy through dispensing records is a useful tool for identifying patients with imporvement possibllity. The healthcare staff must be aware of such non-adherence problem, and try to apply strategies for detecting and improving it throughout the different stages of the care process